Arcus Biosciences has been granted a patent for compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto. These compounds can be used in the treatment and prevention of diseases like cancer and immune-related disorders. GlobalData’s report on Arcus Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Arcus Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Arcus Biosciences's grant share as of April 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds modulating amp to adenosine for treating diseases
A recently granted patent (Publication Number: US11931343B2) discloses a series of compounds represented by formula (Ia) or (Ib), along with their pharmaceutically acceptable salts, hydrates, N-oxides, or solvates. The patent claims cover various specific formulas within this series, providing a detailed scope of protection for these compounds.
Furthermore, the patent also includes claims related to pharmaceutical compositions containing the disclosed compounds along with pharmaceutically acceptable excipients. This indicates the potential use of the compounds for pharmaceutical purposes, highlighting their importance in the field of medicine. Overall, the patent offers a comprehensive protection for the specified compounds and their pharmaceutical compositions, paving the way for potential future developments and applications in the healthcare industry.
To know more about GlobalData’s detailed insights on Arcus Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.